ARTL Partners with ScienceMachine to Accelerate Drug Development
Artelo Biosciences, Inc. announced a strategic partnership with BioAI company ScienceMachine to accelerate the development of its fatty acid-binding protein 5 (FABP5) inhibitor platform. ScienceMachine's AI technology will analyze Artelo's FABP datasets to identify novel biological insights, mechanisms, and therapeutic opportunities for FABP5 inhibitors, particularly ART26.12. The collaboration, which began in 2025, has already identified potential proteins for target engagement and revealed latent biological networks, with preliminary psoriasis model results expected later this year. This partnership is anticipated to enhance R&D precision, accelerate biomarker identification, and prioritize follow-on compounds, shortening the path to value creation.
Key Highlights
- ARTL announced a strategic partnership with BioAI company ScienceMachine.
- The partnership aims to accelerate the development of Artelo's FABP5 inhibitor platform, including ART26.12.
- ScienceMachine's AI platform will analyze Artelo's FABP datasets to identify novel biological insights.
- The collaboration has already identified potential proteins indicative of FABP5 target engagement in ART26.12-treated volunteers.
- Preliminary results from the collaboration in a psoriasis model are slated for publication later this year.
- The partnership identified novel protein and lipid signatures correlated with ART26.12's dose-responsive analgesic effect.
- The collaboration is expected to accelerate identification of novel mechanisms and clinical biomarkers.
- Artelo is the first and only company to bring a selective FABP5 inhibitor into human studies for neuropathic pain.
Price Impact
More from ARTL